Whereas systemic oral treatment with utrophin modulators aim to correct the pathology at later stages of the disease in animal models21, 37 as DMD patients39, the disease is delayed from the initial stages in Fiona mice. Here, UTRN is linked to Duchenne muscular dystrophy.